Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for preeclampsia
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on preeclampsia or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on preeclampsia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Torsemide for Prevention of Persistent Postpartum Hypertension in Women With Preeclampsia: A Randomized Controlled Trial 30303905 2018 10 10 1873-233X 2018 Oct 05 Obstetrics and gynecology Obstet Gynecol Torsemide for Prevention of Persistent Postpartum Hypertension in Women With Preeclampsia: A Randomized Controlled Trial. 10.1097/AOG.0000000000002941 To evaluate whether torsemide reduces the rate of persistent postpartum hypertension in women with preeclampsia. We conducted a randomized (...) , double-blind, placebo-controlled trial of women with preeclampsia at a tertiary center from August 2016 to September 2017. Those with gestational hypertension or renal or cardiopulmonary failure were excluded. Within 24 hours of delivery, women were randomized one to one to oral torsemide, 20 mg/d, or placebo, for 5 days. Our primary outcome was blood pressure greater than or equal to 150 mm Hg systolic or 100 mm Hg diastolic (or both) on two occasions at least 4 hours apart by postpartum day 5
Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial 30055127 2018 10 01 1097-6868 219 4 2018 Oct American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial. 388.e1-388.e17 S0002-9378(18)30606-9 10.1016/j.ajog.2018.07.019 Preterm preeclampsia has a high rate of fetal death or disability. There is no treatment to slow the disease, except delivery (...) . Preclinical studies have identified proton pump inhibitors as a possible treatment. The purpose of this study was to examine whether esomeprazole could prolong pregnancy in women who have received a diagnosis of preterm preeclampsia. We performed a double-blind, randomized controlled trial at Tygerberg Hospital in South Africa. Women with preterm preeclampsia (gestational age 26 weeks+0 days to 31 weeks+6 days) were assigned randomly to 40-mg daily esomeprazole or placebo. The primary outcome
Preeclampsia Top results for preeclampsia - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for preeclampsia The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines
Effect of ibuprofen vs acetaminophen on postpartum hypertension in preeclampsia with severe features: a double-masked, randomized controlled trial 29505772 2018 05 25 1097-6868 218 6 2018 Jun American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Effect of ibuprofen vs acetaminophen on postpartum hypertension in preeclampsia with severe features: a double-masked, randomized controlled trial. 616.e1-616.e8 S0002-9378(18)30175-3 10.1016/j.ajog.2018.02.016 (...) Nonsteroidal antiinflammatory drug use has been shown to increase blood pressure in nonpregnant adults. Because of this, the American College of Obstetricians and Gynecologists suggests avoiding their use in women with postpartum hypertension; however, evidence to support this recommendation is lacking. Our goal was to test the hypothesis that nonsteroidal antiinflammatory drugs, such as ibuprofen, adversely affect postpartum blood pressure control in women with preeclampsia with severe features. At delivery, we randomized
Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit 29505771 2018 05 25 1097-6868 218 6 2018 Jun American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. 612.e1-612.e6 S0002-9378(18)30173-X 10.1016/j.ajog.2018.02.014 Preeclampsia is a major pregnancy complication with adverse (...) short- and long-term implications for both the mother and baby. Screening for preeclampsia at 11-13 weeks' gestation by a combination of maternal demographic characteristics and medical history with measurements of biomarkers can identify about 75% of women who develop preterm preeclampsia with delivery at <37 weeks' gestation and 90% of those with early preeclampsia at <32 weeks, at a screen-positive rate of 10%. A recent trial (Combined Multimarker Screening and Randomized Patient Treatment
Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage 29305829 2018 04 24 1097-6868 218 5 2018 May American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. 483-489 S0002-9378(17)32812-0 10.1016/j.ajog.2017.12.238 Impaired placentation in the first 16 weeks of pregnancy is associated (...) with increased risk of subsequent development of preeclampsia, birth of small-for-gestational-age neonates, and placental abruption. Previous studies reported that prophylactic use of aspirin reduces the risk of preeclampsia and small-for-gestational-age neonates with no significant effect on placental abruption. However, meta-analyses of randomized controlled trials that examined the effect of aspirin in relation to gestational age at onset of therapy and dosage of the drug reported that significant
A study of the diagnostic value of Inhibin A Tests for occurrence of preeclampsia in pregnant women Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir January 2018, Volume: 10, Issue: 1, Pages: 6186-6192, DOI: http://dx.doi.org/10.19082/6186 Corresponding author: Associate Professor Dr. Farzaneh Broumand, Urmia University of Medical Sciences, Urmia, Iran. Tel: +98.9143412320, Fax: +98.4433197656, Emal:email@example.com Received: August 27, 2017, Accepted: October 30, 2017 (...) 6286 A study of the diagnostic value of Inhibin A Tests for occurrence of preeclampsia in pregnant women Farzaneh Broumand 1 , Shaker Salari Lak 2 , Farhad Nemati 3 , Atefeh Mazidi 4 1 M.D., Associate Professor of Gynecology, Urmia University of Medical Sciences, Urmia, Iran 2 Associate Professor of Epidemiology, Department of Public Health, Tabriz Branch, Islamic Azad University, Tabriz, Iran 3 M.D., Cytopathologist, Nemati Clinical Laboratory, Urmia, Iran 4 M.D., Gynecologist, Urmia University
Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history 28784417 2017 11 16 2018 01 11 1097-6868 217 5 2017 11 American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according (...) to their characteristics and medical and obstetrical history. 585.e1-585.e5 S0002-9378(17)30929-8 10.1016/j.ajog.2017.07.038 The Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention trial demonstrated that in women who were at high risk for preterm preeclampsia with delivery at <37 weeks' gestation identified by screening by means of an algorithm that combines maternal factors and biomarkers at 11-13 weeks' gestation, aspirin administration from 11
Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metformin 29225676 2018 11 13 1753-495X 10 4 2017 Dec Obstetric medicine Obstet Med Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metformin. 170-173 10.1177/1753495X17725465 To examine whether the reduced incidence of preeclampsia in non-diabetic obese pregnant women treated with metformin is mediated by changes in insulin resistance. This was a secondary (...) analysis of obese pregnant women in a randomised trial (MOP trial). Fasting plasma glucose and insulin were measured in 384 of the 400 women who participated in the MOP trial. Homeostasis model assessment of insulin resistance (HOMA-IR) was compared in the metformin and placebo groups and in those that developed preeclampsia versus those that did not develop preeclampsia. At 28 weeks, median HOMA-IR was significantly lower in the metformin group. Logistic regression analysis demonstrated
MicroRNAs: New Players in the Pathobiology of Preeclampsia 28993808 2018 11 13 2297-055X 4 2017 Frontiers in cardiovascular medicine Front Cardiovasc Med MicroRNAs: New Players in the Pathobiology of Preeclampsia. 60 10.3389/fcvm.2017.00060 Our understanding of how microRNAs (miRNAs) regulate gene networks and affect different molecular pathways leading to various human pathologies has significantly improved over the years. In contrary, the role of miRNAs in pregnancy-related hypertensive (...) disorders such as preeclampsia (PE) is only beginning to emerge. Recent papers highlight that adverse pregnancy outcomes are associated with aberrant expression of several miRNAs. Presently, efforts are underway to determine the biologic function of these placental miRNAs which can shed light on their contribution to these pregnancy-related disease conditions. The discovery that miRNAs are stable in circulation coupled with the fact that the placenta is capable of releasing them to the circulation
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. Background Preterm preeclampsia is an important cause of maternal and perinatal death and complications. It is uncertain whether the intake of low-dose aspirin during pregnancy reduces the risk of preterm preeclampsia. Methods In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1776 women with singleton pregnancies who were at high risk for preterm preeclampsia to receive aspirin, at (...) a dose of 150 mg per day, or placebo from 11 to 14 weeks of gestation until 36 weeks of gestation. The primary outcome was delivery with preeclampsia before 37 weeks of gestation. The analysis was performed according to the intention-to-treat principle. Results A total of 152 women withdrew consent during the trial, and 4 were lost to follow up, which left 798 participants in the aspirin group and 822 in the placebo group. Preterm preeclampsia occurred in 13 participants (1.6%) in the aspirin group
Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement. Importance: Preeclampsia affects approximately 4% of pregnancies in the United States. It is the second leading cause of maternal mortality worldwide and may lead to serious maternal complications, including stroke, eclampsia, and organ failure. Adverse perinatal outcomes for the fetus and newborn include intrauterine growth restriction, low birth weight, and stillbirth. Many of the complications associated (...) with preeclampsia lead to early induction of labor or cesarean delivery and subsequent preterm birth. Subpopulation Considerations: Preeclampsia is more prevalent among African American women than among white women. Differences in prevalence may be, in part, due to African American women being disproportionally affected by risk factors for preeclampsia. African American women also have case fatality rates related to preeclampsia 3 times higher than rates among white women. Inequalities in access to adequate
Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis 27810551 2016 11 04 2017 02 02 1097-6868 216 2 2017 Feb American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. 121-128.e2 S0002-9378(16)30911-5 10.1016/j.ajog.2016.10.016 The optimum time for commencing antiplatelet (...) therapy for the prevention of preeclampsia and its complications is unclear. Aggregate data meta-analyses suggest that aspirin is more effective if given prior to 16 weeks' gestation, but data are limited because of an inability to place women in the correct gestational age subgroup from relevant trials. The objective of the study was to use the large existing individual participant data set from the Perinatal Antiplatelet Review of International Studies Collaboration to assess whether the treatment
Final recommendation statement: preeclampsia: screening. Final recommendation statement: preeclampsia: screening. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 03 Oct 2017 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed (...) In Username or Email * Password * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Summary NGC:011201 2017 Apr NEATS Assessment Final recommendation statement: preeclampsia: screening. Final recommendation statement: preeclampsia: screening. [internet
Preeclampsia: Screening Final Recommendation Statement: Preeclampsia: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 18.104.22.1688 Last Build: 3/6/2018 4:20:40 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement Preeclampsia: Screening Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare (...) Research and Quality or the U.S. Department of Health and Human Services. Recommendation Summary Population Recommendation Grade Pregnant woman The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy. To read the recommendation statement in JAMA , select . To read the evidence summary in JAMA , select . Table of Contents Preface The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific
The Relationship Between Blood Lead Level and Preeclampsia 28163864 2018 11 13 2008-5842 8 12 2016 Dec Electronic physician Electron Physician The Relationship Between Blood Lead Level and Preeclampsia. 3450-3455 10.19082/3450 Lead is a heavy metal to which people are commonly exposed. One of the possible mechanisms of tissue damages caused by this toxic metal is oxidative stress, which in turn may cause numerous pregnancy complications such as preeclampsia. The present study was conducted (...) to determine the relationship between maternal Blood Lead Level (BLL) and preeclampsia. The present case-control study was conducted on 158 pregnant women admitted to a hospital in Zanjan, Iran, from August 2015 to March 2016. To measure their BLL, 1.5 cc of blood was drawn from each participant. The demographic and obstetric details of the patients were recorded in a form. The potentiometric method was used to test the samples. The data obtained were analyzed by SPSS version 22, using Mann-Whitney U test
The evaluation of serum homocysteine, folic acid, and vitamin B12 in patients complicated with preeclampsia 27957303 2018 11 13 2008-5842 8 10 2016 Oct Electronic physician Electron Physician The evaluation of serum homocysteine, folic acid, and vitamin B12 in patients complicated with preeclampsia. 3057-3061 Increased plasma homocysteine may be associated with adverse pregnancy outcomes, such as preeclampsia. The aim of this study was to determine the plasma homocysteine, serum folate, and (...) vitamin B12 levels in preeclamptic pregnant women. This case-control study was conducted in 2016 in Ahwaz on 51 pregnant women with preeclampsia and 51 healthy pregnant women of the same gestational age, who served as controls. The case group also was subdivided into severe and non-severe preeclampsia. Patients' data were collected through a questionnaire and medical records. Serum homocysteine, folic acid, and vitamin B12 were analyzed using chemiluminescent assay. The results were compared between
Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia 27399996 2016 07 26 2016 07 26 1873-233X 128 2 2016 Aug Obstetrics and gynecology Obstet Gynecol Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia. 261-9 10.1097/AOG.0000000000001525 To assess the association of a serum soluble fms-like tyrosine kinase 1-to-placental growth factor (sFlt-1-to-PlGF (...) ) ratio of greater than 38 with time to delivery and preterm birth. Secondary analysis of an observational cohort study that included women 18 years of age or older from 24 to 36 6/7 weeks of gestation at their first study visit with suspected (not confirmed) preeclampsia. Participants were recruited from December 2010 to January 2014 at 30 sites in 14 countries. A total of 1,041 women were included in time-to-delivery analysis and 848 in preterm birth analysis. Women with an sFlt-1-to-PlGF ratio
Perinatal and Hemodynamic Evaluation of Sildenafil Citrate for Preeclampsia Treatment: A Randomized Controlled Trial 27400005 2016 07 26 2016 07 26 1873-233X 128 2 2016 Aug Obstetrics and gynecology Obstet Gynecol Perinatal and Hemodynamic Evaluation of Sildenafil Citrate for Preeclampsia Treatment: A Randomized Controlled Trial. 253-9 10.1097/AOG.0000000000001518 To evaluate whether therapy with sildenafil citrate prolongs gestation in women with preeclampsia. In a randomized double-blind (...) , placebo-controlled trial, 100 singleton pregnancies with preeclampsia between 24 and 33 weeks of gestation were randomized to 50 mg oral sildenafil citrate every 8 hours or placebo. The primary outcome was prolongation of pregnancy from randomization to delivery. Secondary outcomes were changes in resistance indices of uterine, umbilical, and middle cerebral arteries by Doppler, fetal and maternal complications, and adverse neonatal outcomes. Power analysis estimated that to detect a difference of 5
Protective Role of Maternal P.VAL158MET Catechol-O-Methyltransferase Polymorphism against Early-Onset Preeclampsia and its Complications J Med Biochem 2016; 35 (3) DOI: 10.1515/jomb-2016-0013 UDK 577.1 : 61 ISSN 1452-8258 J Med Biochem 35: 312–318, 2016 Original paper Originalni nau~ni rad PROTECTIVE ROLE OF MATERNAL P .VAL158MET CATECHOL-O- METHYLTRANSFERASE POLYMORPHISM AGAINST EARLY-ONSET PREECLAMPSIA AND ITS COMPLICATIONS ZA[TITNA ULOGA POLIMORFIZMA P .VAL158MET KATEHOL-O-METILTRANSFERAZA (...) of preeclampsia (PE). The goal of this study was to assess the potential correlation between p.Val158Met COMT poly- morphism and risk of early-onset PE, risk of a severe form of early-onset PE, as well as risk of small-for-gestational- age (SGA) complicating PE. Methods: The study included 47 early-onset PE patients and 47 control cases. Forty-seven early-onset PE patients were grouped by disease severity (33 patients with a severe form and 14 patients without severe features) and secondly by size